Shots:

• Celltrion has completed the development of a point-of-care antigen testing kit for COVID-19 in collaboration with BBB. The POCT kit is a portable and overly sensitive device for use in rapid POC testing- thus supporting the early detection of COVID-19+ patients in clinical settings
• Celltrion’s POCT kit demonstrated 95% sensitivity- utilizes lab-on-a-chip technology consisting of a microfluidic electrochemical biosensor to provide results within 15-20 min.- while the company anticipates receiving a CE mark in EU later this month with its expected launch in July
• Additionally- Celltrion has entered into a distribution agreement with Humasis to distribute and commercialize a rapid Ab diagnostic test globally this month. Both the companies will cooperate in the development of an upgraded RDT kit and a rapid antigen diagnostic test- for which Celltrion will apply its COVID-19 antibody-antiviral technology to enhance detection sensitivity

Click here to read full press release/ article | Ref: Celltrion | Image: Celltrion

Related News: Celltrion to Launch Rapid Self-Testing Kit and Accelerates the Development of Treatment Against COVID-19